Biotech | April 05, 2022
Lupin signs deal with Alvion for cardiometabolic drugs in Southeast Asia
Lupin is committed to providing new affordable treatment options to healthcare providers and patients
Lupin is committed to providing new affordable treatment options to healthcare providers and patients
The two-day event will showcase achievements and address issues pertaining to the industry
Sanofi’s DE&I Board will include three of the most influential voices in the DE&I space as Board members appointed for 3 years: organizational psychologist & best-selling author John Amaechi, award-winning social entrepreneur Caroline Casey, and DE&I pioneer and renowned thought-leader Dr. Rohini Anand
CanSinoBIO will continue to focus on developing a variety of innovative preventive vaccines in its diversified product pipeline with proprietary technologies, including the inhaled version of its COVID-19 vaccine, Convidecia
It also secures US $ 10 million for US launch and commercialization
New simplified structure and operational set-up supports Novartis strategy as a focused medicines company and is designed to power next phase of innovation, growth and productivity
The symposium was organized by the Gut Microbiota and Probiotic Science Foundation (India) and Medanta Institute of Education and Research, Gurugram, and Amity University, Gurugram
It aims to make the state-of-the-art modern and safe surgical care, typically available in super-speciality hospitals of big cities, accessible, affordable, standardized and integrated
Intas has developed a biosimilar of Lucentis, which is currently under Phase III global trial for submission in major countries including EMA & the US
Highly prestigious award endowed with €500,000 to uphold the United Nations 2030 Agenda
Subscribe To Our Newsletter & Stay Updated
